Understanding Alzheimer's Symposium
Released
Released
Announcement PDF
UNDERSTANDING ALZHEIMER’S – FROM DISCOVERY RESEARCH TO PATIENT TREATMENT
Sydney, 7 October 2015: Scientists are making important new advancements in the understanding of
Alzheimer’s disease, one of the biggest health issues of our time. Leading experts will gather at a symposium
in Sydney on Monday October 12 to discuss the latest developments including drug discovery and the
advancements in clinical data that are driving renewed interest in the sector. The event, hosted by Actinogen
Medical, will also feature a patient’s perspective on treatment for the disease.
International keynote speaker, Professor Craig Ritchie, Professor of Psychiatry of Aging at Edinburgh
University, a global expert in Alzheimer’s research, will be presenting some of the latest encouraging
developments in treating the disease.
He will be joined by Dr Bryce Vissel from the Garvan Institute to highlight important new basic research
discoveries and speakers from Eli Lilly and Alzheimer’s Australia to provide a better understanding of
Alzheimer’s disease, its treatment and the impact on patients.
Finding a new and effective treatment for Alzheimer’s disease has never been more important. It is already
the second leading cause of death in Australia with 350,000 sufferers; and the number of people diagnosed
with Alzheimer’s is forecast to double within the next 20 years. Current available therapies have limited
benefit and new medicines are desperately needed.
The symposium: Understanding Alzheimer’s – from discovery research to patient treatment will be held at
the Sofitel Hotel in Sydney from 4.30pm. The symposium will be followed by an opportunity to network and
meet the speakers over cocktails and canapes.
Full details of the event are as follows:
Date: Monday, 12 October 2015
Time: 4:30 PM-7:00 PM
Place: Sofitel Sydney Wentworth: 61-101 Phillip Street, Sydney NSW 2000
RSVP: amurphy@buchanwe.com.au or (02) 9237 2804
The speakers include:
•
•
•
Dr Bryce Vissel, Lab Head - Neurodegenerative Diseases, Garvan Institute of Medical Research Alzheimer’s basic research drug discovery
Professor Craig Ritchie, Psychiatry of Ageing, University of Edinburgh - Alzheimer’s clinical research
and drug development
Dr Katarina Kelin, Medical Director of Neuroscience, Eli Lilly (NYSE: LLY) - Commercialising
Alzheimer’s drugs and the state of play in the markets
ACTINOGEN LIMITED TRADING AS ACTINOGEN MEDI CAL ACN 086 778 476 ASX | ACW
Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 8964 7401
WEB www.actinogen.com.au
•
•
Patient advocate, Alzheimer’s Australia - A patient’s perspective on Alzheimer’s disease and
treatment
Dr Bill Ketelbey, CEO, Actinogen Medical (ASX:ACW) - An overview of Actinogen Medical and the
development of its lead drug, Xanamem™
ENDS
Actinogen Medical
Dr Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey
About Xanamem™
Xanamem™ is being developed as a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. The cost of Alzheimer’s treatment in the US alone was estimated to be
US$250bn in 2013, with this cost estimated to increase to US$1 trillion by 2050, outstripping the cost of
treating all other diseases. Alzheimer’s disease is now the second leading cause of death in Australia behind
ischaemic heart disease. Xanamem™’s novel mechanism of action sets it apart from existing Alzheimer’s
treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and
frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is growing evidence that
chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the
development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease.
About Actinogen Medical
Actinogen Medical is focused on the treatment of Alzheimer’s disease and mild cognitive impairment, a
transitional stage of cognitive impairment between normal aging and the more serious condition of
Alzheimer’s dementia. It is developing a novel drug to treat the condition and other age-related
neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which
appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer’s disease. The
Company plans to undertake a Phase II study in mild Alzheimer’s patients in 2016.
ACTINOGEN LIMITED TRADING AS ACTINOGEN MEDI CAL ACN 086 778 476 ASX | ACW
Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 8964 7401
WEB www.actinogen.com.au
Share your feedback
Discover